• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Inflection Point Acquisition Corp. V

    2/13/26 4:09:11 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IPEX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Inflection Point Acquisition Corp. V

    (Name of Issuer)


    Common

    (Title of Class of Securities)


    G6001J107

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G6001J107


    1Names of Reporting Persons

    KARPUS MANAGEMENT, INC.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,016,543.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,016,543.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,016,543.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.54 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Inflection Point Acquisition Corp. V
    (b)Address of issuer's principal executive offices:

    167 Madison Ave, Suite 205 #1017 New York, NY 10016
    Item 2. 
    (a)Name of person filing:

    This statement is being filed by Karpus Management, Inc., d/b/a Karpus Investment Management ("Karpus" or the "Reporting Person"). Karpus is a registered investment adviser under Section 203 of the Investment Advisers Act of 1940. Karpus is controlled by City of London Investment Group plc ("CLIG"), which is listed on the London Stock Exchange. However, in accordance with SEC Release No. 34-39538 (January 12, 1998), effective informational barriers have been established between Karpus and CLIG such that voting and investment power over the subject securities is exercised by Karpus independently of CLIG, and, accordingly, attribution of beneficial ownership is not required between Karpus and CLIG. The Shares to which this Schedule 13G relates are owned directly by the accounts managed by Karpus.
    (b)Address or principal business office or, if none, residence:

    183 Sully's Trail, Pittsford, New York 14534.
    (c)Citizenship:

    The members of the Karpus Management Committee are US citizens. Karpus is a New York corporation.
    (d)Title of class of securities:

    Common
    (e)CUSIP No.:

    G6001J107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1,016,543.00
    (b)Percent of class:

    8.54 %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1,016,543.00

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    1,016,543.00

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    KARPUS MANAGEMENT, INC.
     
    Signature:/s/ Jodi L. Hedberg
    Name/Title:Jodi L. Hedberg / Chief Compliance Officer
    Date:02/13/2026
    Get the next $IPEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IPEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IPEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Trabuco Carolyn

    3 - Inflection Point Acquisition Corp. V (0002028355) (Issuer)

    1/20/26 5:01:12 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Blitzer Michael

    4 - Inflection Point Acquisition Corp. V (0002028355) (Issuer)

    1/5/26 9:41:33 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IPEX
    SEC Filings

    View All

    SEC Form 425 filed by Inflection Point Acquisition Corp. V

    425 - Inflection Point Acquisition Corp. V (0002028355) (Subject)

    4/14/26 9:05:21 AM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inflection Point Acquisition Corp. V filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Inflection Point Acquisition Corp. V (0002028355) (Filer)

    4/14/26 9:00:26 AM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by Inflection Point Acquisition Corp. V

    425 - Inflection Point Acquisition Corp. V (0002028355) (Subject)

    4/3/26 4:21:11 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IPEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GOWell to Host Investor & Analyst Webinar on April 14, 2026

    SINGAPORE and NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- GOWell Technology Limited ("GOWell" or the "Company"), a global one-stop-shop for innovative well logging solutions in the energy sector, will host an Investor & Analyst Webinar on Tuesday, April 14, 2026 at 10:00 a.m. ET. The webinar will include a formal presentation and Q&A session with management. The Company previously announced that it had entered into a Business Combination Agreement with Inflection Point Acquisition Corp. V (NASDAQ:IPEX) ("IPEX"), on October 14, 2025. To register for this webinar, please use the registration link found here. Additionally, for those unable to listen to the live webcast, a recording will be

    3/31/26 6:00:00 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GOWell Technology Limited and Inflection Point Acquisition Corp. V Announce Public Filing of Registration Statement on Form F-4 in Connection with Proposed Business Combination

    SINGAPORE and NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- GOWell Technology Limited ("GOWell" or the "Company"), a global one-stop-shop for innovative well logging solutions in the energy sector, and Inflection Point Acquisition Corp. V (NASDAQ:IPEX) ("Inflection Point"), a special purpose acquisition company, have announced the public filing of their joint registration statement on Form F-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") related to their previously announced business combination (the "Business Combination"). The Registration Statement contains a preliminary proxy statement/prospectus of Inflection Point that discloses importan

    3/25/26 6:03:49 PM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GOWell Technology Participates in Advanced Well Integrity Benchmarking Program Coordinated by an Independent Net Zero Organization

    SINGAPORE and NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- GOWell Technology Limited ("GOWell" or the "Company"), a global one-stop-shop for innovative well logging solutions in the energy sector, today announced its participation in a collaborative effort to evaluate next generation well integrity technologies. The evaluation was performed as part of an industry benchmarking program led by an independent Net Zero organization at the NORCE testing facility in Stavanger, Norway. This initiative assessed cutting-edge methods designed to address the industry's most urgent operational and sustainability challenges in well integrity evaluation. As global decommissioning activities accelerate, o

    12/18/25 8:30:00 AM ET
    $IPEX
    Biotechnology: Pharmaceutical Preparations
    Health Care